A Study to Investigate the Effectiveness and Safety of Bempedoic Acid in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia in Taiwan
← catalyst calendarSponsored by Daiichi Sankyo (industry) · 4568.T — their whole pipeline →.
Phase
Phase 4
Status
Completed
Study type
Interventional
Design
Na · None · Treatment
Enrollment
180actual
Sites
3
Country
Taiwan
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-04-01 | actual | When the study began enrolling |
| Primary completion | 2025-10-15 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-10-15 | actual | The whole study's end, after follow-up |
| First posted | 2025-04-13 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-12-08 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Primary Hypercholesterolemia or Mixed Hyperlipidemia
Intervention
- Drug: Bempedoic acid 180 mg tablet
Primary outcome
what the primary-completion date above is the date OFPercentage change from baseline in LDL-C level at Week 12
measured 12 weeks
Publications
- PMID 42134976 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · 4568.T's whole pipeline · Catalyst calendar · Every registered study · What changed